

## **KRAS-WT/SOS1 BINDING ASSAY KITS**

PROTOCOL

Part # 63ADK000CB15PEG & 63ADK000CB15PEH

Test size: 500 tests (63ADK000CB15PEG), 10,000 tests (63ADK000CB15PEH) - assay volume: 20 µL

Revision: 01 (February 2020) Store at: -60°C or below

This product is intended for research purposes only. The product is not intended to be used for

therapeutic or diagnostic purposes.

#### **ASSAY PRINCIPLE**

The HTRF KRAS-WT/SOS1 Binding Assay is designed to measure the interaction between KRAS-WT and SOS1 proteins. Utilizing HTRF (Homogeneous Time-resolved Fluorescence) technology, the assay enables simple and rapid characterization of compound and antibody blockers in a high throughput format.

As shown in Figure 1, the interaction between Tag1-SOS1 and Tag2-KRAS-WT is detected by using anti-Tag1-Terbium (HTRF donor) and anti-Tag2-XL665 (HTRF acceptor). When the donor and acceptor antibodies are brought into close proximity due to SOS1 and KRAS-WT binding, excitation of the donor antibody triggers fluorescent resonance energy transfer (FRET) towards the acceptor antibody, which in turn emits specifically at 665 nm. This specific signal is directly proportional to the extent of KRAS-WT/SOS1 interaction. Thus, compound or antibody blocking KRAS-WT/SOS1 interaction will cause a reduction in HTRF signal.





Figure 1: Principle of the HTRF KRAS-WT/SOS1 assay.

## PROTOCOL AT A GLANCE



Make sure to use the setup for Tb³+ Cryptate. For more information about set-up and compatible HTRF® readers, please visit our website at: http://www.cisbio.com/readers



#### **MATERIALS:**

KIT COMPONENTS	500 TESTS CAT # 63ADK000CB15PEG	10,000 TESTS CAT # 63ADK000CB15PEH		
To ~ 1 CO C 1 *	1 vial	1 vial		
Tag1-SOS1* MW: 58.8 kDa	25 μL 500 X	420 μL 500 X		
IVIVV. 30.0 KDa	Frozen	Frozen		
Togo VDAC VAT *	1 vial	1 vial		
Tag2-KRAS-WT * MW: 20.2 kDa	25 μL 500 X	420 μL 500 X		
VIVV. 20.2 KDa	Frozen	Frozen		
	1 vial	1 vial		
Anti-Tag1-Tb³+	25 μL	500 μL		
Allu-lagi-lb	100 X	100 X		
	Frozen	Frozen		
	1 vial	1 vial		
Anti-Tag2-XL665	50 μL			
Allti-Tag2-AL003	50 X			
	Frozen	Lyophilized		
	1 vial	1 vial		
Diluont	20 mL	200 mL		
Diluent	Cat# 62DLBDDF (200 mL)	Cat# 62DLBDDF		
	ready-to-use	ready-to-use		
	1 vials	1 vial		
Detection Buffer	10 mL	130 mL		
Detection bullet	Cat# 62DB2FDG (130 mL)	Cat# 62DB2FDG (130 mL)		
	ready-to-use	ready-to-use		

<sup>\*</sup> The amounts of Tag1-SOS1 and Tag2-KRAS-WT provided are sufficient for the validated amounts of tagged proteins suitable for compound inhibition study: optimized concentrations of SOS1 and KRAS-WT in 20 µL final assay volume.

Additional material (Not provided): GTP (SIGMA, V900868).

For reading, an HTRF®-Certified Reader is needed.

For HTRF microplate recommendations, please visit http://www.cisbio.com/microplate-recommendations For a list of HTRF-compatible readers and setup recommendations, please visit http://www.cisbio.com/readers

## STORAGE AND STABILITY



Store the kit at -60°C or below. Under appropriate storage conditions, reagents are stable until the expiry date indicated on the label.



Once thawed, tagged SOS1 & KRAS-WT stock solution may be frozen, and can be thawed only once. Once thawed (or reconstituted), anti-Tag solutions can be frozen once.

To avoid freeze/thaw cycles, it is recommended to dispense remaining stock solutions into disposable plastic vials for storage at -60°C or below.

Thawed diluent and detection buffer can be stored at 2-8°C on your premises.

#### **REAGENT PREPARATION**

#### **BEFORE YOU BEGIN:**

- It is very important to prepare reagents in the specified buffers. The use of an incorrect diluent may affect reagent stability and assay results.
- · Thaw the frozen reagents at room temperature.
- Before use, allow all reagents to warm up to room temperature then homogeneize buffer and diluent. It is recommended to filter buffers before use.
- The tagged protein solutions must be prepared in individual vials DO NOT premix tagged solutions prior to dispensing.
- The anti-Tag solutions must be prepared in individual vials and can be premix prior to dispensing.
- Compounds may be prepared in diluent. We recommend keeping DMSO below 0.5% during the assay (20 μL final volume).

#### TO PREPARE WORKING SOLUTIONS:

Take care to prepare stock and working solutions according to the directions for the kit size you have purchased.

500 TESTS 10,000 TESTS

Tag1-SOS1 protein
500 X stock solution of optimized final concentration

Thaw the Tag1-SOS1 protein\* solution.

Dilute 100-fold the 500 X Tag1-SOS1 protein stock solution with diluent buffer to prepare a 5 X working solution. e.g. 5 µL of thawed Tag1-SOS1 protein stock solution + 495 µL of diluent buffer. (20 µL final volume).

Tag2-KRAS-WT protein
500 X stock solution of optimized final concentration

Thaw the Tag2-KRAS-WT protein\* solution.

Dilute 100-fold the 500 X Tag2-KRAS-WT protein stock solution with diluent buffer to prepare a 5 X working solution. e.g. 5 µL of thawed Tag2-KRAS-WT protein stock solution + 495 µL of diluent buffer. (20 µL final volume).

Anti-Tag1-Tb3+

Thaw the anti-Tag1-Tb3+ solution.

This 100 X stock solution can be frozen and stored at -60°C or below.

Dilute 100-fold the 100 X anti-Tag1-Tb<sup>3+</sup> stock solution with detection buffer to prepare a 1 X working solution.

e.g. 25  $\mu$ L of thawed anti-Tag1-Tb³+ stock solution + 2475  $\mu$ L of detection buffer.

e.g.  $0.5~\mathrm{mL}$  of thawed anti-Tag1-Tb $^{3+}$  stock solution + 49.5 mL of detection buffer.

#### Anti-Tag2-XL665

Thaw the anti-Tag2-XL665 solution.

This 50 X stock solution can be frozen and stored at -60°C or below.

Reconstitute lyophilized anti-Tag2-XL665 with 1 mL of distilled water. This allows to a 50 X stock solution, that can be frozen and stored at -60°C or below.

Dilute 50-fold the 50 X anti-Tag2-XL665 stock solution with detection buffer. e.g. 50  $\mu$ L of thawed anti-Tag2-XL665 stock solution + 2450  $\mu$ L of detection buffer.

Dilute 50-fold the 50 X anti-Tag2-XL665 stock solution with detection buffer. e.g. 1.0 mL of reconstituted anti-Tag2-XL665 stock solution + 49.0 mL of detection buffer.

#### **ASSAY PROTOCOL**

Step 1		Dispense 2 μL of compound/antibody or diluent 4 μL of Tag1-SOS1 protein 4 μL of Tag2-KRAS-WT protein
Step 2	<b>⊙↓</b>	Incubate for 15 minutes at room temperature.
Step 3		Dispense 10 μL of pre-mixed anti-Tag1-Tb³+ and anti-Tag2-XL665.
Step 4	<b>⊙↓</b>	Seal the plate and incubate for over night (+GTP) at room temperature.
Step 5		Remove the plate sealer and read on an HTRF® compatible reader.

<sup>\*</sup>Titration of Tag1-SOS1 or Tag2-KRAS-WT can be performed if necessary.

## STANDARD PROTOCOL FOR INHIBITORY ASSAY IN 20 µL FINAL VOLUME

	Inhibitor	Tag1-SOS1	Tag2-KRAS-WT	Anti-Tag1- Tb³+	Anti-Tag2- XL665	Diluent	Detection buffer
Sample	2 μL	4 μL	4 μL	5 μL	5 μL		
Positive control		4 μL	4 μL	5 μL	5 μL	2 μL	
Negative control		4 μL		5 μL	5 μL	6 μL	
Cryptate control				5 μL		10 μL	5 μL
Buffer control						10 μL	10 μL

## **EXAMPLE OF PLATE MAP**

	1	2	3	4	5	6
A	Buffer control: 10 μL diluent 10 μL detection buffer	Repeat Well A1	Repeat Well A1	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well A4	Repeat Well A4
В	Cryptate control: 10 μL diluent 5 μL detection buffer 5 μL anti-Tag1-Tb	Repeat Well B1	Repeat Well B1	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well B4	Repeat Well B4
С	Negative control: 6 μL diluent 4 μL Tag1-SOS1 10 μL pre-mix anti-Tag reagents	Repeat Well C1	Repeat Well C1	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well C4	Repeat Well C4
D	Positive control:  2 µL diluent  4 µL Tag1-SOS1  4 µL Tag2-KRAS-WT  10 µL pre-mix anti-Tag reagents	Repeat Well D1	Repeat Well D1	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well D4	Repeat Well D4
E	Compound 1: 2 μL compound 1 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well E1	Repeat Well E1	Compound:	Repeat Well E4	Repeat Well E4
F	Compound 2: 2 μL compound 2 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well F1	Repeat Well F1	Compound:	Repeat Well F4	Repeat Well F4
G	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well G1	Repeat Well G1	Compound:	Repeat Well G4	Repeat Well G4
н	Compound: 2 μL compound 4 μL Tag1-SOS1 4 μL Tag2-KRAS-WT 10 μL pre-mix anti-Tag reagents	Repeat Well H1	Repeat Well H1			

#### **DATA REDUCTION & INTERPRETATION**

1. Calculate the ratio of the acceptor and donor emission signals for each individual well.


Ratio = 
$$\frac{\text{Signal 665 nm}}{\text{Signal 620 nm}} \times 10^4$$


2. Calculate the % CVs. The mean and standard deviation can then be worked out from ratio replicates.

For more information about data reduction, please visit http://www.cisbio.com/data-reduction

### **APPLICATION NOTE**


To investigate the difference between nude KRAS and GTP bound KRAS, the IC50 values of inhibitors are measured in KRAS/SOS1 and GTP-KRAS/SOS1 binding assays.






GTP-KRASWT/SOS1, IC<sub>50</sub>=12.30 nM

## KRASWT/SOS1 binding assay Inhibitory effect of SOS1 inhibitor (Incubation for over night)




GTP-KRAS<sup>WT</sup>/SOS1, IC<sub>50</sub>=11.67 nM

## KRASWT/SOS1 binding assay Inhibitory effect of KRAS(G12C) inhibitor (Incubation for 2 h)



KRASWT/SOS1 GTP-KRAS $^{\mathrm{WT}}$ /SOS1, IC<sub>50</sub> >200  $\mu$ M

KRASWT/SOS1 binding assay Inhibitory effect of KRAS(G12C) inhibitor (Incubation for over night)



KRASWT/SOS1

GTP-KRAS $^{WT}$ /SOS1, IC<sub>50</sub> >200  $\mu$ M

#### STANDARD PROTOCOL FOR GTP BOUND KRAS ASSAY IN 20 µL FINAL VOLUME

# To carry out GTP bound KRAS assay, please replace the working solution preparation step of Tag2-KRAS-WT protein with following steps:

Take care to prepare stock and working solutions according to the directions for the kit size you have purchased.

Prepare 10 mM stock solution of GTP in distilled water. All guanosine phosphate derivatives are unstable and solutions should be made fresh immediately before use. Recommended final concentration of GTP: 10 µM.

GTP bound Tag2-KRAS-WT protein 500 X stock solution of optimized final concentration

Thaw the Tag2-KRAS-WT protein\* solution.

Dilute 100-fold the 500 X Tag2-KRAS-WT protein stock solution and 200-fold the 10 mM GTP stock solution with diluent buffer to prepare a 5 X working solution.

e.g. 5 µL of Tag2-KRAS-WT protein stock solution + 2.5 µL of 10 mM GTP stock solution + 492.5 µL of diluent buffer. (20 µL final volume).

Reagent	Final conc. (nM)	Working conc. (nM)	Stock conc. (nM)	Dilution ratio	Volume of Stock (μL)	Volume of Diluent (μL)	Volume of TOTAL (μL)
Tag2-KRAS-WT protein	1 X	5 X	500 X	100	5	492.5	500.0
GTP	10,000	50,000	10,000,000	200	2.5	492.5	300.0

#### **RESULTS**


The data shown below must not be substituted for the data obtained in the laboratory, and should be considered only as an example.


The inhibitory effects of small molecules were tested at optimized concentrations of SOS1 and KRAS-WT.

Readouts on PHERAstar FS with laser.

Note that results may vary from one HTRF® compatible reader to another.


Inhibitor	Vender	Cat#	Description
AMG 510	Selleck	S8830	An effective covalent inhibitor of KRAS(G12C) which has potential anti-tumor activity.
6H05	Selleck	S7330	A selective, allosteric inhibitor of KRAS(G12C).
KRAS(G12C) inhibitor 12	Selleck	S7331	An allosteric inhibitor of KRAS(G12C).
ARS-1620	Selleck	S8707	An effective covalent inhibitor of KRAS(G12C) with oral activity.
KRpep-2d	Selleck	S8499	A selective inhibitory cyclic peptide of KRAS(G12D). Comparing with KRAS(WT) and KRAS(G12C), it has higher selectivity to KRAS(G12D).
AZ 628	Selleck	S2746	A novel inhibitor of pan-RAF.
PLX-4720	Selleck	S1152	An effective, selective inhibitor of BRAF(V600E).
BAY-293	Selleck	S8826	An effective covalent inhibitor of SOS1. It can selectively inhibit the KRAS/SOS1 interaction.






- AMG 510, IC<sub>50</sub>=98.17 μM
- ightharpoonup 6H05, IC<sub>50</sub> > 200  $\mu$ M
- -- KRAS-G12C Inhibitor 12, IC<sub>50</sub> > 200 μM
- --- ARS-1620, IC<sub>50</sub> > 200 μM

## GTP-KRAS<sup>WT</sup>/SOS1 binding assay Inhibitory effect of small molecules (Incubation for over night)




- AZ 628, IC<sub>50</sub> > 200 μM
- -- PLX-4720, IC<sub>50</sub> > 200 μM
- ▼ BAY-293, IC<sub>50</sub>=11.65 nM

## GTP-KRAS<sup>G12C</sup>/SOS1 binding assay Inhibitory effect of small molecules (Incubation for over night)



- AMG 510, IC<sub>50</sub>=49.53 nM
- → 6H05, IC<sub>50</sub>=4.195 μM
- -- KRAS-G12C Inhibitor 12, IC<sub>50</sub>=6.495 μM
- → ARS-1620, IC<sub>50</sub>=237.8 nM

## GTP-KRAS<sup>G12C</sup>/SOS1 binding assay Inhibitory effect of small molecules (Incubation for over night)



- KRpep-2d, IC<sub>50</sub>=718.7 nM
- $\triangle$  AZ 628, IC<sub>50</sub> > 200  $\mu$ M
- PLX-4720, IC<sub>50</sub> > 200  $\mu$ M
- **▼** BAY-293, IC<sub>50</sub>=13.77 nM

This product contains material of biologic origin. Use for research purposes only. Do not use in humans or for diagnostic purposes. The purchaser assumes all risk and responsibility concerning reception, handling and storage.

Copyright 2017 Cisbio, France. All rights reserved. HTRF®, Tag-lite®, and EPIgeneous™ are trademarks or registered trademarks of Cisbio All other trademarks are the property of their respective owners.

